New Investigational Drug for HSV
New CEO of Squarex, Jack V. Talley discusses the positive results of the phase 2 study on their new investigational drug candidate SQX770, a topical immunomodulator treatment to extend the time between herpes labialis (recurrent cold sores) outbreaks caused by Herpes Simplex Virus 1 or Herpes Simplex Virus 2. Squarex is a clinical-stage pharmaceutical company.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Treatment. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Treatment and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Treatment?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Jack Talley is a seasoned biopharmaceutical industry executive with a depth of business and drug development experience amassed during a 30-year career that started at Sanofi. He was named the chief executive officer at Squarex in July 2019, and also serves on the board of Mitotherapeutix, a privately-held company using siRNA for a novel protein target that affects mitochondrial metabolism, such as liver disease.
Previously, Jack served as CEO for five clinical-stage drug companies over a 19-year span, during which he took three companies public. Most recently, Mr. Talley served as CEO, President and Director of Izun Pharmaceuticals, where he oversaw the spinoff of the company’s dental business and the approval of three products by the U.S. Food & Drug Administration and the European Medicines Agency.
Mr. Talley received his B.S. in Chemistry from the University of Connecticut and completed coursework towards an M.B.A. in Marketing from New York University, Graduate School of Business.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
